Cambridge, UK., 3rd May 2019: Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology, ArestatTM to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a collaboration with a new major global pharmaceutical partner.
Under the collaboration, Arecor will leverage its ArestatTM technology to develop superior liquid formulations of its partner’s proprietary products. The partner will fund the development work and has the option to acquire the rights to the formulation and associated Intellectual Property under a technology licensing model.
This partnership further demonstrates the value of Arecor’s ArestatTM technology platform in delivering superior therapeutic treatments that are otherwise not achievable.
Sarah Howell, Chief Executive Officer at Arecor, said: “This new partnership with a major pharmaceutical company further strengthens our pipeline of commercial projects within our formulation technology business. Our commercial relationships with pharmaceutical partners represent the opportunity to showcase both our technology and scientific expertise. With the option to grant an exclusive licence to the formulation developed, we potentially have an ongoing role to support our pharmaceutical partner in the development of their superior therapeutic products.”
For more information, please contact:
Dr Sarah Howell, Chief Executive Officer
Tel: +44 (0) 1223 426060
Susan Lowther, Chief Financial Officer
Tel: +44 (0) 1223 426060
Mob : +44 (0) 7879 458 364
Email : firstname.lastname@example.org
Notes to Editors
About Arecor (www.arecor.com)
Arecor Limited is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor’s product portfolio also includes:
• Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
• Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices,
• Stable aqueous glucagon for emergency and artificial pancreas use, and
• A series of undisclosed pre-clinical programmes.
Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science